FULGENT GENETICS, INC. Debt Securities, Available-for-sale, Realized Loss
FULGENT GENETICS, INC. (FLGT) reported Debt Securities, Available-for-sale, Realized Loss of $0 for the 12-month period ending 2025-12-31, per its 10-K filed 2026-02-27.
Financial Statements › Income Statement › Other Income
us-gaap:DebtSecuritiesAvailableForSaleRealizedLoss · last filed 2026-02-27
- FULGENT GENETICS, INC. debt securities, available-for-sale, realized loss for the quarter ending 2024-12-31 was $100.00K, a 83.33% decline year-over-year.
- FULGENT GENETICS, INC. debt securities, available-for-sale, realized loss for the quarter ending 2024-09-30 was $100.00K.
- FULGENT GENETICS, INC. debt securities, available-for-sale, realized loss for the quarter ending 2024-06-30 was $300.00K.
- FULGENT GENETICS, INC. debt securities, available-for-sale, realized loss for the quarter ending 2024-03-31 was $600.00K.
- FULGENT GENETICS, INC. debt securities, available-for-sale, realized loss for fiscal 2025 was $0.00, a 100.00% decline from fiscal 2024.
- FULGENT GENETICS, INC. debt securities, available-for-sale, realized loss for fiscal 2024 was $1.10M, a 83.33% increase from fiscal 2023.
- FULGENT GENETICS, INC. debt securities, available-for-sale, realized loss for fiscal 2023 was $600.00K, a 57.14% decline from fiscal 2022.
- FULGENT GENETICS, INC. debt securities, available-for-sale, realized loss for fiscal 2022 was $1.40M.
| Period end | Debt Securities, Available-for-sale, Realized Loss 3 month | Debt Securities, Available-for-sale, Realized Loss 6 month | Debt Securities, Available-for-sale, Realized Loss 9 month | Debt Securities, Available-for-sale, Realized Loss 12 month |
|---|---|---|---|---|
| 2025-12-31 | $0.00 10-K · filed 2026-02-27 | |||
| 2024-12-31 | $100.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-27 | $200.00K derived: sum of 2 quarters · filed 2026-02-27 | $500.00K derived: sum of 3 quarters · filed 2026-02-27 | $1.10M 10-K · filed 2026-02-27 |
| 2024-09-30 | $100.00K 10-Q · filed 2025-11-07 | $400.00K derived: sum of 2 quarters · filed 2025-11-07 | $1.00M 10-Q · filed 2025-11-07 | $1.60M derived: sum of 4 quarters · filed 2026-02-27 |
| 2024-06-30 | $300.00K 10-Q · filed 2025-08-01 | $900.00K 10-Q · filed 2025-08-01 | $1.50M derived: sum of 3 quarters · filed 2026-02-27 | $1.50M derived: sum of 4 quarters · filed 2026-02-27 |
| 2024-03-31 | $600.00K 10-Q · filed 2025-05-02 | $1.20M derived: sum of 2 quarters · filed 2026-02-27 | $1.20M derived: sum of 3 quarters · filed 2026-02-27 | $1.20M derived: sum of 4 quarters · filed 2026-02-27 |
| 2023-12-31 | $600.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-27 | $600.00K derived: sum of 2 quarters · filed 2026-02-27 | $600.00K derived: sum of 3 quarters · filed 2026-02-27 | $600.00K 10-K · filed 2026-02-27 |
| 2023-09-30 | $0.00 10-Q · filed 2024-11-08 | $0.00 derived: sum of 2 quarters · filed 2024-11-08 | $0.00 10-Q · filed 2024-11-08 | |
| 2023-06-30 | $0.00 10-Q · filed 2024-08-02 | $0.00 10-Q · filed 2024-08-02 | ||
| 2022-12-31 | $1.40M 10-K · filed 2025-02-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| BIODESIX INC (BDSX) | United States | $0.312B | |
| Lumexa Imaging Holdings, Inc. (LMRI) | United States | $0.951B | |
| EXAGEN INC. (XGN) | United States | $0.212B | -5.95 |
| Freenome, Inc. (FRNM) | United States | $0.143B | |
| CASTLE BIOSCIENCES INC (CSTL) | United States | $1.074B | -37.45 |
| SERA PROGNOSTICS, INC. (SERA) | United States | $0.062B | -5.75 |
| AMERICAN SHARED HOSPITAL SERVICES (AMS) | United States | $0.010B | -5.64 |
| Advanced Biomed Inc. (ADVB) | $0.009B | ||
| Aclarion, Inc. (ACON) | United States | $0.008B | |
| BioNexus Gene Lab Corp (BGLC) | $0.004B |